RNA標的低分子創薬の市場規模、シェア、動向分析レポート：適応症別、最終用途別、地域別、セグメント予測、セグメント予測、2025年～2030年

RNA標的低分子創薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のRNA標的低分子創薬市場規模は、2025年から2030年にかけて21.9%のCAGRを記録し、2030年までに54億2,000万米ドルに達すると推定されています。

RNA標的低分子創薬産業は、様々な疾患に対する標的化された効果的な治療薬を開発する可能性があるため、急成長を続けています。

がん、遺伝性疾患、ウイルス感染などの疾患の有病率の増加が、RNA標的低分子薬の需要を煽っています。RNA標的低分子創薬産業は、CRISPR-Cas9やRNA干渉のような最先端技術の導入により劇的に成長しました。これらの技術により、疾病の発症に関与するRNA標的の同定が可能となり、RNAを標的とする全く新しい低分子医薬品が生み出されています。

今後数年間、創薬のためのRNA標的低分子市場は、製薬会社やバイオテクノロジー企業による研究開発活動への出費の増加に牽引され、大幅な拡大が見込まれます。革新的なRNA標的低分子を創製するプロセスには時間とコストがかかるが、集中的で効率的な治療という潜在的な報酬が得られるため、投資に値します。

例えば、2020年にモデナがバーテックス・ファーマシューティカルズと共同で行った嚢胞性線維症治療用のRNA標的低分子医薬品の開発は、この分野への重要な投資です。モデナは自社のmRNA技術プラットフォームを使って新規RNA標的を同定し、バーテックスは低分子創薬の専門知識を応用して標的に対する治療法を開発します。この提携は、疾患治療に革命をもたらす可能性を秘めたRNA標的低分子創薬への関心と投資の高まりを反映しています。

RNA標的低分子創薬市場レポートハイライト

• 適応症ではがんが予測期間中22.3%と最も高いCAGRを示しました。同分野の高成長は、がんの有病率の増加と、より効果的な治療法の緊急ニーズによるところが大きいです。
• RNA標的低分子創薬業界では、製薬・バイオ製薬企業がエンドユーザー・セグメントで優位を占めており、2024年の市場シェアは59.4%でした。これは、この分野における研究開発活動への多額の投資と、新薬を市場に投入するための専門知識によるものです。
• 北米は2024年に世界市場の60.7%という最大の売上シェアを占めたが、これは主要市場プレイヤーの存在、高度なヘルスケアインフラ、研究開発活動への投資の増加といった要因によるものです。同地域は、新治療法の開発と商業化を支援する医療制度が確立されており、これが同市場における優位性の一因となっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 RNA標的低分子創薬市場の変数、動向、および範囲

• 市場系統の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析

第4章 RNA標的低分子創薬市場：適応症別ビジネス分析

• 適応症市場シェア、2024年および2030年
• 適応症セグメントダッシュボード
• 市場規模、予測、動向分析（適応症別、2018～2030年）
• がん
• 感染症
• 代謝性疾患
• 神経疾患
• その他

第5章 RNA標的低分子創薬市場：最終用途別ビジネス分析

• 最終用途市場シェア、2024年および2030年
• 最終用途セグメントダッシュボード
• 市場規模、予測、動向分析（最終用途別、2018～2030年）
• 製薬会社およびバイオ医薬品会社
• 学術研究機関
• その他

第6章 RNA標的低分子創薬市場：地域別推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 市場規模、予測動向分析、2018年から2030年まで：
• 北米
  • 国別、2018年～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 国別、2018年～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • デンマーク
  • スウェーデン
• アジア太平洋
  • 国別、2018年～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • 国別、2018年～2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 国別、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/リスト
  • ACCENT THERAPEUTICS
  • Anima Biotech Inc.
  • Arrakis Therapeutics
  • AstraZeneca
  • Epics Therapeutics
  • Expansion Therapeutics
  • F. Hoffmann-La Roche Ltd
  • PTC Therapeutics, Inc.
  • Ribometrix
  • LES LABORATOIRES SERVIER
  • Skyhawk Therapeutics

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global RNA targeting small molecule drug discovery market, by region, 2018 - 2030 (USD Million)
• Table 4. Global RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 5. Global RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 6. North America RNA targeting small molecule drug discovery market, by country, 2018 - 2030 (USD Million)
• Table 7. North America RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 8. North America RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 9. U.S. RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 10. U.S. RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 11. Canada RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 12. Canada RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 13. Mexico RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 14. Mexico RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 15. Europe RNA targeting small molecule drug discovery market, by country, 2018 - 2030 (USD Million)
• Table 16. Europe RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 17. Europe RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 18. UK RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 19. UK RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 20. Germany RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 21. Germany RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 22. France RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 23. France RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 24. Italy RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 25. Italy RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 26. Spain RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 27. Spain RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 28. Norway RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 29. Norway RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 30. Denmark RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 31. Denmark RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 32. Sweden RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 33. Sweden RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 34. Asia Pacific RNA targeting small molecule drug discovery market, by country, 2018 - 2030 (USD Million)
• Table 35. Asia Pacific RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 36. Asia Pacific RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 37. Japan RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 38. Japan RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 39. China RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 40. China RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 41. India RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 42. India RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 43. Australia RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 44. Australia RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 45. South Korea RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 46. South Korea RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 47. Thailand RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 48. Thailand RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 49. Latin America RNA targeting small molecule drug discovery market, by country, 2018 - 2030 (USD Million)
• Table 50. Latin America RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 51. Latin America RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 52. Brazil RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 53. Brazil RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 54. Argentina RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 55. Argentina RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 56. Middle East & Africa RNA targeting small molecule drug discovery market, by country, 2018 - 2030 (USD Million)
• Table 57. Middle East & Africa RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 58. Middle East & Africa RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 59. South Africa RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 60. South Africa RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 61. Saudi Arabia RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 62. Saudi Arabia RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 63. UAE RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 64. UAE RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)
• Table 65. Kuwait RNA targeting small molecule drug discovery market, by indication, 2018 - 2030 (USD Million)
• Table 66. Kuwait RNA targeting small molecule drug discovery market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 RNA targeting small molecule drug discovery market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Indication and end use outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 RNA targeting small molecule drug discovery market dynamics
• Fig. 12 RNA targeting small molecule drug discovery market: Porter's five forces analysis
• Fig. 13 RNA targeting small molecule drug discovery market: PESTLE analysis
• Fig. 14 RNA targeting small molecule drug discovery market: Indication segment dashboard
• Fig. 15 RNA targeting small molecule drug discovery market: Indication market share analysis, 2024 & 2030
• Fig. 16 Cancer market, 2018 - 2030 (USD Million)
• Fig. 17 Infectious diseases market, 2018 - 2030 (USD Million)
• Fig. 18 Metabolic diseases market, 2018 - 2030 (USD Million)
• Fig. 19 Neurological diseases market, 2018 - 2030 (USD Million)
• Fig. 20 Others market, 2018 - 2030 (USD Million)
• Fig. 21 RNA targeting small molecule drug discovery market: End use segment dashboard
• Fig. 22 RNA targeting small molecule drug discovery market: End use market share analysis, 2024 & 2030
• Fig. 23 Pharmaceutical and biopharmaceutical companies market, 2018 - 2030 (USD Million)
• Fig. 24 Academic and research institutes market, 2018 - 2030 (USD Million)
• Fig. 25 Others market, 2018 - 2030 (USD Million)
• Fig. 26 RNA targeting small molecule drug discovery market revenue, by region
• Fig. 27 Regional marketplace: Key takeaways
• Fig. 28 Regional marketplace: Key takeaways
• Fig. 29 North America RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 30 U.S. country dynamics
• Fig. 31 U.S. RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 32 Canada country dynamics
• Fig. 33 Canada RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 34 Mexico country dynamics
• Fig. 35 Mexico RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 36 Europe RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 37 UK country dynamics
• Fig. 38 UK RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 39 Germany country dynamics
• Fig. 40 Germany RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 41 France country dynamics
• Fig. 42 France RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 43 Italy country dynamics
• Fig. 44 Italy RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 45 Spain country dynamics
• Fig. 46 Spain RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 47 Norway country dynamics
• Fig. 48 Norway RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 49 Sweden country dynamics
• Fig. 50 Sweden RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 51 Denmark country dynamics
• Fig. 52 Denmark RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 53 Asia Pacific RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 54 Japan country dynamics
• Fig. 55 Japan RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 56 China country dynamics
• Fig. 57 China RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 58 India country dynamics
• Fig. 59 India RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 60 Australia country dynamics
• Fig. 61 Australia RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 62 South Korea country dynamics
• Fig. 63 South Korea RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 64 Thailand country dynamics
• Fig. 65 Thailand RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 66 Latin America RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 67 Brazil country dynamics
• Fig. 68 Brazil RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 69 Argentina country dynamics
• Fig. 70 Argentina RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 71 MEA RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 72 South Africa country dynamics
• Fig. 73 South Africa RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 74 Saudi Arabia country dynamics
• Fig. 75 Saudi Arabia RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 76 UAE country dynamics
• Fig. 77 UAE RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 78 Kuwait country dynamics
• Fig. 79 Kuwait RNA targeting small molecule drug discovery market, 2018 - 2030 (USD Million)
• Fig. 80 Company categorization
• Fig. 81 Company market position analysis
• Fig. 82 Strategic framework

RNA Targeting Small Molecule Drug Discovery Market Growth & Trends:

The global RNA targeting small molecule drug discovery market size is estimated to reach USD 5.42 billion by 2030, registering a CAGR of 21.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. RNA-targeting small molecule drug discovery industry continues to undergo rapid growth due to its potential to develop targeted and effective therapeutics for various diseases.

The increasing prevalence of diseases such as cancer, genetic disorders, and viral infections has fueled the demand for RNA-targeting small-molecule drugs. The RNA-targeting small molecule drug discovery industry has grown dramatically as a result of the introduction of cutting-edge technologies like CRISPR-Cas9 and RNA interference. These technologies have made it possible to identify RNA targets that are implicated in the pathogenesis of diseases, which has resulted in the creation of brand-new small-molecule medications that target RNA.

In the upcoming years, the market for RNA targeting small molecules for drug discovery is anticipated to experience significant expansion, driven by the rising expenditure in R&D activities by pharmaceutical and biotechnology businesses. The process of creating innovative, RNA-targeting small molecules is time-consuming and costly, but the potential rewards of focused, efficient treatments make it a worthy investment.

For instance, in 2020 Moderna's recent collaboration with Vertex Pharmaceuticals to develop RNA-targeted small molecule drugs for the treatment of cystic fibrosis is a significant investment in this field. Moderna will use its mRNA technology platform to identify novel RNA targets, while Vertex will apply its expertise in small molecule drug discovery to develop therapies for the targets. This collaboration reflects the growing interest and investment in RNA-targeting small molecule drug discovery, which has the potential to revolutionize disease treatment.

RNA Targeting Small Molecule Drug Discovery Market Report Highlights:

• Cancer in the indication segment witnessed the highest CAGR of 22.3% ovre the forecast period. The high growth of the segment is majorly due to the increasing prevalence of cancer and the urgent need for more effective treatments.
• Pharmaceutical and biopharmaceutical companies dominated the RNA-targeting small molecule drug discovery industry in the end-user segment, with a market share of 59.4% in 2024. This is due to their significant investment in research and development activities in this field, as well as their expertise in bringing new drugs to market.
• North America held the maximum revenue share of 60.7% of the global market in 2024, due to factors such as the presence of key market players, advanced healthcare infrastructure, and increasing investment in research and development activities. This region has a well-established healthcare system that supports the development and commercialization of new therapies, which contributes to its dominance in the market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. RNA Targeting Small Molecule Drug Discovery Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. RNA Targeting Small Molecule Drug Discovery Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2030
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 4.4. Cancer
  • 4.4.1. Cancer Market, 2018 - 2030 (USD Million)
• 4.5. Infectious Diseases
  • 4.5.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
• 4.6. Metabolic Diseases
  • 4.6.1. Metabolic Diseases Market, 2018 - 2030 (USD Million)
• 4.7. Neurological Diseases
  • 4.7.1. Neurological Diseases Market, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. RNA Targeting Small Molecule Drug Discovery Market: End Use Business Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Pharmaceutical and Biopharmaceutical Companies
  • 5.4.1. Pharmaceutical and Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
• 5.5. Academic and Research Institutes
  • 5.5.1. Academic and Research Institutes Market, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. RNA Targeting Small Molecule Drug Discovery Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Norway
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Norway RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Denmark RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. ACCENT THERAPEUTICS
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Anima Biotech Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Arrakis Therapeutics
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. AstraZeneca
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Epics Therapeutics
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Expansion Therapeutics
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. F. Hoffmann-La Roche Ltd
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. PTC Therapeutics, Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Ribometrix
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. LES LABORATOIRES SERVIER
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Skyhawk Therapeutics
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic Initiatives